ORY — ORYZON Genomics SA Share News
0.000.00%
Last trade - 00:00- €204.89m
- €196.06m
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28
Corrected: BRIEF-Oryzon Genomics H1 Net Loss At €1.4 Mln
Brief: Oryzon Gets U.S. Patent Grant For Vafidemstat In Borderline Personality Disorder
Oryzon slumps after discounted share placement
Brief: Oryzon Completes Accelerated Bookbuild Offering At 2.70 Eur/Shr
Spanish stocks - Factors to watch on July 1
Brief: Oryzon Launches ABB Offer For €10 Mln Capital Increase
Brief: Oryzon Presents Updated Positive Clinical Data For Iadademstat In AML
Spanish stocks - Factors to watch on May 15
Spain's Oryzon Genomics' Q1 net loss widens on higher R&D costs
Brief: Oryzon Genomics Q1 Income From Operations USD -6.666 Million
Brief: Oryzon Q1 Net Loss 1.2 Mln Euros
Spanish stocks - Factors to watch on March 25
Brief: Oryzon Gets US Patent Allowance For Vafidemstat
Spanish stocks - Factors to watch on March 23
Brief: Oryzon Announces US Patent Grant Covering Iadademstat Combinations For AML